NASDAQ:PGNXProgenics Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Progenics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.10 -0.42 (-9.29 %) (As of 07/9/2020 04:00 PM ET) Add Compare Share Today's Range$3.94Now: $4.10▼$4.7950-Day Range$3.63MA: $4.18▼$4.6252-Week Range$1.89Now: $4.10▼$6.37Volume34.93 million shsAverage Volume1.16 million shsMarket Capitalization$355.05 millionP/E RatioN/ADividend YieldN/ABeta1.89 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProgenics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Progenics Pharmaceuticals has a potential upside of 192.7% from its current price of $4.10.Amount of Analyst CoverageProgenics Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesProgenics Pharmaceuticals has received 414 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProgenics Pharmaceuticals has received 379 “underperform” votes. (Add your “underperform” vote.)Community SentimentProgenics Pharmaceuticals has received 52.21% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote “Outperform” if you believe PGNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProgenics Pharmaceuticals does not currently pay a dividend.Dividend GrowthProgenics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Progenics Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.26% of the stock of Progenics Pharmaceuticals is held by insiders.Percentage Held by Institutions70.96% of the stock of Progenics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Progenics Pharmaceuticals are expected to grow in the coming year, from ($0.85) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progenics Pharmaceuticals is -5.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Progenics Pharmaceuticals is -5.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProgenics Pharmaceuticals has a P/B Ratio of 7.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:PGNX Previous Symbol CUSIP74318710 CIK835887 Webwww.progenics.com Phone646-975-2500Debt Debt-to-Equity Ratio0.99 Current Ratio2.12 Quick Ratio2.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.99 million Price / Sales10.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book7.59Profitability EPS (Most Recent Fiscal Year)($0.80) Net Income$-68,550,000.00 Net Margins-180.28% Return on Equity-129.46% Return on Assets-53.23%Miscellaneous Employees79 Outstanding Shares86,597,000Market Cap$355.05 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:PGNX Rates by TradingView Receive PGNX News and Ratings via Email Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter. Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions How has Progenics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Progenics Pharmaceuticals' stock was trading at $3.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PGNX shares have increased by 7.6% and is now trading at $4.10. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Progenics Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Progenics Pharmaceuticals. When is Progenics Pharmaceuticals' next earnings date? Progenics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Progenics Pharmaceuticals. How were Progenics Pharmaceuticals' earnings last quarter? Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.03. The biotechnology company earned $6.25 million during the quarter. Progenics Pharmaceuticals had a negative net margin of 180.28% and a negative return on equity of 129.46%. View Progenics Pharmaceuticals' earnings history. What price target have analysts set for PGNX? 2 brokers have issued 12 month target prices for Progenics Pharmaceuticals' stock. Their forecasts range from $10.00 to $14.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $12.00 in the next year. This suggests a possible upside of 192.7% from the stock's current price. View analysts' price targets for Progenics Pharmaceuticals. Has Progenics Pharmaceuticals been receiving favorable news coverage? Press coverage about PGNX stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Progenics Pharmaceuticals. Who are some of Progenics Pharmaceuticals' key competitors? Some companies that are related to Progenics Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Progenics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), Imax (IMAX), Novavax (NVAX), Cara Therapeutics (CARA), Opko Health (OPK), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX). Who are Progenics Pharmaceuticals' key executives? Progenics Pharmaceuticals' management team includes the following people: Mr. Mark R. Baker, CEO & Director (Age 64)Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)Mr. Benedict Osorio, Chief Operating Officer (Age 62)Dr. Vivien Wong, Exec. VP of Devel. (Age 62)Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46) What is Progenics Pharmaceuticals' stock symbol? Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX." How do I buy shares of Progenics Pharmaceuticals? Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Progenics Pharmaceuticals' stock price today? One share of PGNX stock can currently be purchased for approximately $4.10. How big of a company is Progenics Pharmaceuticals? Progenics Pharmaceuticals has a market capitalization of $355.05 million and generates $34.99 million in revenue each year. The biotechnology company earns $-68,550,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe. What is Progenics Pharmaceuticals' official website? The official website for Progenics Pharmaceuticals is www.progenics.com. How can I contact Progenics Pharmaceuticals? Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected] This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
